×

Novo Nordisk A/S: FDA posts briefing materials prior to Advisory Committee meeting for Saxenda(r) for the treatment of obesity

BAGSVAERD, Denmark, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 11 September 2014 Advisory Committee meeting to discuss the New Drug Application (NDA) for Saxenda®, the intended brand name forliraglutide 3 mg for the treatment of obesity.

Further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 55 / 2014

Company announcement No 55 / 2014 http://hugin.info/2013/R/1854659/648657.pdf

HUG#1854659

Source:Novo Nordisk A/S